Juan Rafael de la Haba Rodríguez

Has grant

Profesor Titular

Universidad de Córdoba

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Cancer Biology Cancer Biology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Juan Rafael de la Haba Rodríguez is a Profesor Titular at Universidad de Cordoba, Spain. His research focuses on oncology, particularly in the areas of colorectal cancer and hormone receptor-positive breast cancer, as evidenced by his recent publications. He has contributed to studies on targeted therapies, medication adherence, and the impact of various treatment regimens on patient outcomes.

Recent Grants

Grant: Close

PT17/0017/0032 Plataforma de Unidades de Investigación Clinica y Ensayos Clínicos

Open Date: 2020-01-01

Close Date:

Grant: Close

Caracterizacion Molecular del cancer de Mama Gestacional

Open Date: 2019-01-01

Close Date: 2021-12-01

Grant: Close

Perfil epigenético en pacientes oncológicos con incrementos de la presión arterial secundaria a tratamiento con anti-VEGF

Open Date: 2016-01-01

Close Date: 2018-12-01

Grant: Close

ANALISIS DE LOS POLIMORFISMOS RELACIONADOS CON HIPERTENSION ARTERIAL COMO FACTOR PREDICTIVO DE RESPUESTA AL TRATAMIENTO ANTIANGIOGENICO EN CANCER

Open Date: 2012-01-01

Close Date: 2014-12-01

Grant: Close

EVALUATION OF AGTR1 EXPRESSION IN TUMORS AS A POSSIBLE PREDICTOR OF RESPONSE TO ANTIANGIOGENIC THERAPY IN CONNECTION WITH THE CLINICAL DEVELOPMENT OF BEVACIZUMAB

Open Date: 2011-01-01

Close Date: 2013-12-01

Articles (17)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (12)

Mothaffar Rimawi

Professor, Executive Medical Director

Baylor College of Medicine

UNITED STATES

View details

Enrique Aranda Aguilar

Profesor Titular de Universidad

Universidad de Córdoba

SPAIN

View details

Tiziana Triulzi

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

Aurelio Moya Garcia

University College London

UNITED KINGDOM

View details

Jeremy Braybrooke

Honorary Associate Professor

University of Bristol

UNITED KINGDOM

View details

Jonas Bergh

Karolinska University Hospital

SWEDEN

View details

Alejandra Pera

Lecturer

Universidad de Córdoba

SPAIN

View details

Mireia Margeli Vila

Universitat Autònoma de Barcelona (UAB)

SPAIN

View details

Greg Yothers

Research Professor

University of Pittsburgh

UNITED STATES

View details

Serena Di Cosimo

Open University

UNITED KINGDOM

View details

Junichiro Watanabe

Professor

Juntendo University

JAPAN

View details

Miguel Martin

Universidad Complutense de Madrid

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Juan Rafael de la Haba Rodríguez

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (17)

Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis

Clinical significance of glycogen synthase kinase 3 (GSK-3) expression and tumor budding grade in colorectal cancer: Implications for targeted therapy

Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology.

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.

Quality of life with palbociclib plus fulvestrant <i>versus</i> placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.

Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial.

The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial

Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal-Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab

Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)

Role of germline variants in the metastasis of breast carcinomas

SEOM-GETTHI clinical guideline for the practical management of molecular platforms (2021)

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Medication Non-Adherence in Rheumatology, Oncology and Cardiology: A Review of the Literature of Risk Factors and Potential Interventions.

Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.

A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy.

Collaborators (12)

Mothaffar Rimawi

Enrique Aranda Aguilar

Tiziana Triulzi

Aurelio Moya Garcia

Jeremy Braybrooke

Jonas Bergh

Alejandra Pera

Mireia Margeli Vila

Greg Yothers

Serena Di Cosimo

Junichiro Watanabe

Miguel Martin

Make your next move.